Eloxx Pharmaceuticals in the spotlight (part II)

Enrollment update and market overreaction to COO resignation

This post is a continuation of our part I assessment of ELOX fundamentals and market timing. Yesterday, ELOX was down 17% to $1.60 after the company provided an enrollment update for ELX-02 Phase 2 in cystic fibrosis (CF). The company expects to present data from the first 4 monotherapy cohorts in Q4 2021. This was in line with our expectations of earl…